These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 16549970

  • 1. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL.
    AIDS; 2006 Apr 04; 20(6):863-70. PubMed ID: 16549970
    [Abstract] [Full Text] [Related]

  • 2. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.
    HIV Med; 2009 Apr 04; 10(4):229-35. PubMed ID: 19178592
    [Abstract] [Full Text] [Related]

  • 3. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE.
    J Med Virol; 2010 Sep 04; 82(9):1481-8. PubMed ID: 20648600
    [Abstract] [Full Text] [Related]

  • 4. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
    Pal A, Sarkar N, Saha D, Guha SK, Saha B, Chakrabarti S, Chakravarty R.
    Antivir Ther; 2015 Sep 04; 20(5):545-54. PubMed ID: 25654813
    [Abstract] [Full Text] [Related]

  • 5. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.
    Antivir Ther; 2008 Sep 04; 13(3):341-8. PubMed ID: 18572746
    [Abstract] [Full Text] [Related]

  • 6. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F, Vincenti D, Vairo F, Solmone M, Mariano A, Piselli P, Puro V, Capobianchi MR, Antonucci G.
    J Med Virol; 2009 Jul 04; 81(7):1151-6. PubMed ID: 19475624
    [Abstract] [Full Text] [Related]

  • 7. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2007 Nov 04; 79(11):1650-4. PubMed ID: 17854040
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.
    Ann Biol Clin (Paris); 2002 Nov 04; 60(5):581-8. PubMed ID: 12368144
    [Abstract] [Full Text] [Related]

  • 9. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
    Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T.
    Hepatology; 1999 Nov 04; 30(5):1302-6. PubMed ID: 10534354
    [Abstract] [Full Text] [Related]

  • 10. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
    Tuma P, Pineda JA, Labarga P, Vidal F, Rodriguez C, Poveda E, Santos J, Gonzalez-García J, Sobrino P, Tural C, Soriano V, CoRIS Study Group.
    Antivir Ther; 2011 Nov 04; 16(4):585-9. PubMed ID: 21685546
    [Abstract] [Full Text] [Related]

  • 11. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI.
    J Med Virol; 2009 Mar 04; 81(3):441-5. PubMed ID: 19152397
    [Abstract] [Full Text] [Related]

  • 12. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC, Haverkamp MH, Weersink AJ, Boucher CA, Hoepelman IM.
    Ned Tijdschr Geneeskd; 2004 Nov 20; 148(47):2330-4. PubMed ID: 15587052
    [Abstract] [Full Text] [Related]

  • 13. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
    Bellini C, Keiser O, Chave JP, Evison J, Fehr J, Kaiser L, Weber R, Vernazza P, Bernasconi E, Telenti A, Cavassini M, Swiss HIV Cohort Study.
    HIV Med; 2009 Jan 20; 10(1):12-8. PubMed ID: 18795964
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
    Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J.
    AIDS; 2003 Jul 25; 17(11):1649-57. PubMed ID: 12853747
    [Abstract] [Full Text] [Related]

  • 15. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.
    Antivir Ther; 2009 Jul 25; 14(5):649-54. PubMed ID: 19704167
    [Abstract] [Full Text] [Related]

  • 16. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.
    Antivir Ther; 2005 Jul 25; 10(6):727-34. PubMed ID: 16218172
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
    Hsieh TH, Tseng TC, Liu CJ, Lai MY, Chen PJ, Hsieh HL, Chen DS, Kao JH.
    Antivir Ther; 2009 Jul 25; 14(8):1157-63. PubMed ID: 20032545
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA.
    AIDS; 2007 Aug 20; 21(13):1701-10. PubMed ID: 17690567
    [Abstract] [Full Text] [Related]

  • 19. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME.
    J Clin Virol; 2006 May 20; 36(1):60-3. PubMed ID: 16418013
    [Abstract] [Full Text] [Related]

  • 20. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 May 20; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.